Second Nonhormonal Drug for Menopausal Hot Flashes : AJN The American Journal of Nursing

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

Drug Watch

Aschenbrenner, Diane S. MS, RN

Author Information

Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected].

AJN, American Journal of Nursing | DOI: 10.1097/01.NAJ.0000995344.24718.f2 Metrics Abstract   Fezolinetant (Veozah) has been approved to treat severe vasomotor symptoms—also called hot flashes—during menopause. Adverse effects of treatment include abdominal pain, diarrhea, insomnia, back pain, hot flashes, and elevations in hepatic transaminases. Nurses and NPs should confirm that liver function studies are completed at baseline and at three, six, and nine months after starting therapy. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. Full Text Access for Subscribers:

You can read the full text of this article if you:

Select an optionLog InBuy ArticleSubscribeContent & PermissionsAccess through Ovid

Log In Access through Ovid Article Level Metrics Readers Of this Article Also Read